肝细胞癌的分期与治疗策略

Abstract

Abstract: A accurate staging system for hepatocellular carcinoma(HCC) should address all of these issues to help predict survival outcomes and decide optimal treatment strategies.In this review article,currently available integrated staging systems including the Okuda classification,the American Jiont Committee on Cancer and International Union on Against Cancer TNM stage (TNM),the Cancer of the Liver Italian Program (CLIP),the French classification,the Barcelona Clinic Liver Cancer (BCLC),Japan Integrated Scoring (JIS),Chinese University Prognostic Index (CUPI) are presented,and their characteristics and applicability for current HCC patients are assessed.This will be important for us to use those classifications rationally when we treat HCC patients and analysis prognostic evaluation system,and also facilitate to compare with similar foreign data.We hope to establish a new staging systems for common use in China based on other currently classification systems.

Key words: Hepatocellular carcinoma, Stage, Treatment strategies

CLC Number:

R735.7

ZHAN Wan-guang, ZHANG Bi-xiang. Treatment strategies based on evaluation of staging systems for hepatocellular carcinoma[J]. Surgical Research and New Technique, 2013, 2(4): 251-254.

References

[1]Chen XP,Huang ZY.Surgical treatment of hepatocellular carcinoma in China:surgical techniques,indications,and outcomes[J].Langenbecks Arch Surg,2005,390(3):259-265.
[2] Chung H,Kudo M,Takahashi S,et al.Review of current staging systems for hepatocellular carcinoma [J].Hepatol Res,2007,37(Suppl 2):S210-S215.
[3] Okuda K,Ohtsuki T,Obata H,et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment Study of 850 patients [J].Cancer,1985,56(4):918-928.
[4] Fleming ID,Cooper JS,Henson DE,et al.Liver AJCC cancer staging manual (ed 5) [M].Philadelphia:Lippincott-Raven,1997:98-126.
[5] Huang ZY,Chen G,Hao XY,et al.Outcomes of non-anatomic liver resection for hepatocellular carcinoma in the patients with liver cirrhosis and analysis of prognostic factors[J].Langenbecks Arch Surg,2011,396(2):193-199.
[6] Kee KM,Wang JH,Lin CY,et al.Validation of the 7th edition TNM staging system for hepatocellular carcinoma:an analysis of 8,828 patients in a single medical center [J].Dig Dis Sci,2013,58(9):2721-2728.
[7] Chun YH,Kim SU,Park JY,et al.Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma [J].Eur J Cancer,2011,47(17):2568-2575.
[8] Llovet JM,Bruix J.Prospective validation of the Cancer of the Liver Italian Program (CLIP) score:a new prognostic system for patients with cirrhosis and hepatocellular carcinoma [J].Hepatology,2000,32(3):679-680.
[9] Chevret S,Trinchet JC,Mathieu D,et al.A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].J Hepatol,1999,31(1):133-141.
[10] Llovet JM,Brú C,Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification[J].semi Liver Dis,1999,19(3):329-338.
[11] Chen XP,Qiu FZ,Wu ZD,et al.Long-term outcome of resection of large hepatocellular carcinoma[J].Br J Surg,2006,93(5):600-606.
[12] Chen XP,Qiu FZ,Wu ZD,et al.Chinese experience with hepatectomy for huge hepatocellular carcinoma[J].Br J Surg,2004,91(3):322-326.
[13] Leung TWT,Tang AMY,Zee B,et al.Construction of the Chinese University Prognostic Index for hepatocellular carcinomaand comparison with the TNM staging system,the Okuda staging system,and the Cancer of the Liver Italian Program staging system [J].Cancer,2002,94(6):1760-1769.
[14] Kudo M,Chung H,Osaki Y.Prognostic staging system for hepatocellular carcinoma (CLIP score):its value and limitations,and a proposal for a new staging system,the Japan Integrated Staging Score (JIS score) [J].J Gastroenterol,2003,38(3):207-215.
[15] 杨秉辉,夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324.
[16] Yang T,Zhang J,Lu JH,et al.A new staging system for resectable hepatocellular carcinoma:comparison with six existing staging systems in a large Chinese cohort [J].J Cancer Res Clin,2011,137(5):739-750.
[17] Choi SB,Lee JG,Kim KS,et al.The prognosis and survival analysis according toseven staging systems of hepatocellular carcinoma following curative resection [J].Hepato-gastroenterol,2008,55(88):2140.
[18] Lu W,Dong J,Huang Z,et al.Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection:Okuda,CLIP,TNM and CUPI [J].J Gastroen Hepatol,2008,23(12):1874-1878.
[19] Marrero JA,Kudo M,Bronowicki JP.The challenge of prognosis and staging for hepatocellular carcinoma [J].Oncologist,2010,15(4):23-33.
[20] FD Huitzil-Melendez,Marinela Capanu,Eileen M.O’Reilly,et al.Advanced Hepatocellular Carcinoma:Which Staging Systems Best Predict Prognosis? [J].J Clin Oncol,2010,17(28):2889-2895.
[21] Testa R,Testa E,Giannini E,et al.Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis:role of combined staging systems,Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD),in predicting outcome after treatment [J].Aliment Pharm Therap,2003,17(12):1563-1569.
[22] Vauthey JN,Ribero D,Abdalla EK,et al.Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma:validation of a uniform staging after surgical treatment [J].J Am Coll Surg,2007,204(5):1016-1027.
[23] Villa E,Colantoni A,Cammà C,et al.Estrogen receptor classification for hepatocellular carcinoma:comparison with clinical staging systems [J].J Clin Oncol,2003,21(3):441-446.

Treatment strategies based on evaluation of staging systems for hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 14

Recommended Articles

Metrics

Comments

[1]	XU Yiyi. Standardized management of medical device users [J]. Surgical Research and New Technique, 2021, 10(1): 70-73.
[2]	LIU Pengfei, XU Wen, LIU Kai, YE Chun. Differential diagnosis between atypical hepatic abscess and hepatocellular carcinoma [J]. Surgical Research and New Technique, 2019, 8(3): 187-188.
[3]	DU Shenhua. Clinical effects of traditional Chinese medicine formula and endoscopic intervention on acute biliary pancreatitis at early stage [J]. Surgical Research and New Technique, 2018, 7(3): 184-186.
[4]	GE Haiyan, ZHANG Zhenyu, FU Zhengwei, JI Fang, GAO Wei, GU Yueming, WANG Zhiqiang, MA Weiwei. Relationship between circulating tumor cells and clinical pathologic stages in patients with colon cancer [J]. Surgical Research and New Technique, 2018, 7(1): 1-3.
[5]	. Comparative efficacy of radiofrequency ablation of small hepatocellular carcinoma TACE combined with sequential treatment with surgical resection [J]. Surgical Research and New Technique, 2016, 5(4): 237-240.
[6]	. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): Breaks the barrier between resectable and unresectable. [J]. Surgical Research and New Technique, 2016, 5(3): 201-207,215.
[7]	Yue-Zu FAN. Study on treatment methods based on different stages for plasma cell mastitis [J]. Surgical Research and New Technique, 2014, 3(2): 119-121.
[8]	TANG Zhao-you. Approaches to improvement of survival after surgery for hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 213-215.
[9]	YE Shenglong. Multidisciplinary comprehensive therapy  for primary liver cancer [J]. Surgical Research and New Technique, 2013, 2(4): 216-218.
[10]	ZHAO Ze-ming, Becker Thomas, FAN Yue-zu, Ringe Bastian, Klempnauer Jürgen. Hepatocellular carcinoma (HCC) & liver transplantation (LT) [J]. Surgical Research and New Technique, 2013, 2(4): 219-224.
[11]	WANG Jie. Anti-HBV playing an important role in therapy of hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 225-228.
[12]	ZHANG Yao-jun, CHEN Min-shan. Multi-disciplinary treatment for recurrent hepatocellular carcinoma after hepatectomy:current status and prospect [J]. Surgical Research and New Technique, 2013, 2(4): 255-258.
[13]	LI Yun-tong, LUO Shun-feng, LIU Jing-feng. Advances in research on prediction for early postoperative metastasis and recurrence in patients with hepatocellular carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 259-261.
[14]	YANG Fan, ZHANG Qi, CHEN Gui-hua. Cellular immunotherapy of hepatocellar carcinoma [J]. Surgical Research and New Technique, 2013, 2(4): 262-266.